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Cardiology
These pages profile the 
kinds of impressive 
accomplishments in 
research, education, and 
patient care that make me 
proud to lead Jefferson’s 
Department of Medicine. 
On the research front, 
we are honored to announce that Dr. Koch and 
a team of Jefferson scientists were awarded an 
$11.6 million grant from the National Heart, 
Lung, and Blood Institute to study cardiac injury 
and repair. In the clinical arena, our Cardiology 
Division was recognized for its outstanding 
performance in meeting the quality standards set 
forth by the Centers for Medicare and Medicaid 
Services. In education, the Internal Medicine 
Clerkship Program, under Dr. Diemer’s direction, 
demonstrates our commitment to deepening 
students’ medical education. Other articles feature 
the important work of Dr. Bergmeier and division 
chiefs Dr. Cheung and Dr. Irigoyen.
I would like to thank several of the generous 
donors (featured on page 5) who play an invaluable 
role in supporting our initiatives. Together, our 
researchers, clinicians, educators, and supporters 
are the substance behind the Department of 
Medicine’s well-regarded reputation. Please also 
visit our department website at www.jefferson.edu/
medicine for more in-depth articles and updates 
on our activities.
Arthur M. Feldman, MD, PhD
Magee Professor of Medicine and 
Chairman of the Department
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The National Heart, Lung, and Blood 
Institute (NHLBI) has awarded Jefferson 
scientists an $11.6 million grant for the 
study of cardiac injury and repair. Three of 
the four labs funded by the grant are part 
of the Department of Medicine’s Center for 
Translational Medicine, which oversees the 
department’s research activities. The fourth 
lab belongs to Steven R. Houser, Chair of 
the Department of Physiology at Temple 
University Medical Center.
Principal Investigator for this programmatic 
award is Walter J. Koch, PhD, the W. W. 
Smith Professor of Medicine and Director 
of the Center for Translational Medicine; 
Dr. Koch is also Director of the Center’s 
George Zallie and Family Laboratory of 
Cardiovascular Gene Therapy. “Much of 
the project will focus on the science of 
cardiac failure and repair with the goal of 
understanding and developing new therapies,” 
says Dr. Koch. “We are also working with 
stem cells and pharmaceuticals that patients 
already receive.”
The study examines molecular mechanisms as 
well as the potential for processes that might 
repair a failing heart in adults, in the hopes of 
generating data that could eventually result 
in new therapies. Along with Dr. Koch (at 
far left), support in administrative, surgical, 
molecular cell biology, and gene therapy will 
come from Center faculty members (see left; 
clockwise from top right: Andrea Eckhart, 
PhD; Joseph Rabinowitz, PhD; Ehre Gao, 
MD, PhD; and Patrick Most, MD).
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2Keynote speaker Stephen B. Ligget, MD (above, 
left), Professor of Medicine and Physiology receives 
the Excellence in Translational Science Award 2008 
in appreciation of his outstanding contributions to 
translational cardiovascular and pulmonary research 
from the Director of the Center for Translational 
Medicine and W.W. Smith Professor of Medicine 
Walter J. Koch, PhD (above, right).
The Center for Translational Medicine’s annual 
symposium, held June 5, 2008, showcased the 
Center’s diverse interests in translational 
science ranging from pulmonology, hematology, 
rheumatology, and developmental biology to 
the cardiovascular field. ■
4th Annual 
Symposium
C e n t e r  f o r  T r a n s l a t i o n a l  M e d i c i n e
Patrick Most, MD (far right), Assistant 
Professor and Director of the Laboratory for 
Stem Cell and Gene Therapy at the Center 
for Translational Medicine, received an 
NIH Research Project Grant (or RO1) for 
more than $1.9 million. The study is entitled 
“S100A1: A novel modulator of myocardial 
infarct inflammation and regeneration.” 
Dr. Most began work in April 2008 and the 
grant runs through March 2013. 
On May 9, 2008, Heather I. Cohn successfully 
defended her PhD dissertation, entitled “The 
role of GRK2 in high blood pressure,” mak-
ing her the first doctoral student to graduate 
from the Center. Her advisor was Associate 
Professor Andrea Eckhart, PhD, Director of 
the Center’s Eugene Feiner Laboratory for 
Vascular Biology and Thrombosis.
On March 28, 2008, Washingtonpost.com 
featured a story about the Center for 
Translational Medicine’s basic research on the 
signaling protein called Gi and its critical role 
in protecting the heart during a heart attack. 
The full findings were published in the March 
18, 2008, issue of the journal Circulation.
For more, see www.jeffersonhospital.org/
news/2007/article15918.html. ■
Center News
Paulina Oca, MS 
(above) and David 
Harris, PhD (right) 
received the 
4th Center for 
Translational Medicine Excellence in Science Award 
for their presentations “TGFβ regulation of ANKH 
(progressive ankylosis) expression in ATDC5 cells” 
(Ms. Oca) and “Targeted inhibition of Gq-signaling 
improves beta-adrenergic receptor mediated cardiac 
function following hypertension” (Dr. Harris).
Presenting scientists and organizing committee of 
the Center for Translational Medicine’s 4th annual 
symposium: Front row, left to right: Que-Xian Zhang, 
PhD; X. Li, PhD; Yanrong Su, PhD; Jee In Kim, PhD; 
Wolfgang Bergmeier, PhD; Raihana Zaka, PhD. Back 
row, left to right: Donjun Li, PhD; Susan Moraca; 
Walter J. Koch, PhD (Director of the Center for 
Translational Medicine); A. Kondkar, PhD; Carolin 
Kraus, MD; Dave Harris, PhD; Paulina Oca, MS; 
Patrick Most, MD (Symposium Director); Yajing 
Wang, MD, PhD; David Rohde, MD; Stephen B. 
Liggett, MD (keynote speaker); Jeffrey Martini, PhD.
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Wolfgang Bergmeier, PhD, runs a laboratory 
in Jefferson’s Curtis Building with two other 
researchers that focuses on the problem of 
thrombosis (blood clotting) at a molecular 
level. After doing undergraduate work in 
his native Germany, he did postgraduate 
training at Harvard Medical School and 
the Immune Disease Institute. He joined 
Jefferson in early 2008 to build upon the 
Division of Hematology and the research 
program at Jefferson’s Cardeza Foundation 
Hemophilia Center.
Investigating Arterial Thrombosis
Dr. Bergmeier’s work deals with the signaling 
pathways regulating platelet activation and 
adhesion. Platelets are best known for their 
critical role in arterial thrombosis, that is, 
in pathological conditions such as heart 
attack and stroke. “Arterial thrombosis 
is the formation of a thrombus within an 
artery, a process driven by the uncontrolled 
accumulation of platelets,” says Dr. 
Bergmeier. “If these thrombi grow too 
New Research Examines the Science Behind Blood Clots
3
Wolfgang Bergmeier, PhD, leads a research team in Hematology that studies new ways to prevent arterial thrombosis.
Hematology
big, they can obstruct blood flow through 
the circulatory system, leading to ischemia 
and infarction of vital organs such as the 
heart or the brain. Coronary heart disease is 
responsible for 1 in 5 deaths in the U.S., and 
ischemic heart disease is still the leading cause 
of death in developed countries.”
Issues of Anti-Thrombotics
Dr. Bergmeier’s lab is currently studying 
new ways to inhibit platelet adhesion and 
therefore thrombus formation. “The agents 
used to prevent arterial thrombosis are platelet 
inhibitors,” he explains. They aim at blocking 
platelet adhesion, and some directly target 
integrins, the adhesion receptors expressed on 
the platelet surface (such as ReoPro®). Others 
inhibit molecules important for the activation 
of these receptors (such as aspirin or Plavix®). 
“The problem of anti-thrombotics,” says Dr. 
Bergmeier, “is that they also affect hemostasis,” 
which is the physiological process whereby 
bleeding is halted. “So the question becomes 
whether a drug can effectively block thrombosis 
while not significantly affecting hemostasis.”
Understanding Integrin Activation
To begin to answer this question, the lab has 
made major progress in the regulation of 
platelet integrins, the receptors on the surface 
of the cell that act as a kind of Velcro that 
binds the cells together. “When the platelets 
get sticky enough,” Dr. Bergmeier says, “they 
start forming thrombi. And while this is 
crucial for hemostasis, it also can cause a heart 
attack or a stroke. The signaling cascades 
regulating integrin activation are complex 
and interlinked, but there has been substantial 
progress in identifying the important players 
in this process,” he says.
Dr. Bergmeier’s recent work has identified 
a protein called CalDAG-GEFI as one of 
these central regulators of integrin activation 
in platelets. “Our studies demonstrate 
that CalDAG-GEFI is important for the 
near-immediate activation of integrins 
in stimulated platelets, a process that is 
absolutely required for the cell to adhere at 
the site of vascular damage,” he says. Dr. 
Bergmeier has published related articles 
in Nature Medicine, the Journal of Clinical 
Investigation, and Blood.
This basic research studies platelet function in 
mice and is done in vitro (outside the animal) 
and in vivo (inside the animal). He uses a 
cutting-edge intravital microscopy approach 
to study thrombus formation in arterioles of 
living mice. “It’s still a mouse model, so we 
have to be careful when we make predictions 
on how successful targeting a particular 
protein would be in humans,” he says. “But 
studying platelet adhesion to sites of vascular 
damage in vivo, or under most physiological 
conditions, has become the gold standard for 
evaluating new targets.”  
Targeting Proteins 
Dr. Bergmeier’s studies suggest that CalDAG-
GEFI cooperates with P2Y12, the target of 
the antithrombotic drug Plavix®, in various 
aspects of platelet activation. His studies 
suggest that targeting CalDAG-GEFI may 
be more effective than Plavix with regard 
to reducing thrombus formation. He is 
currently validating these observations in 
other models of arterial thrombosis. “We are 
very excited about our collaboration with 
Dr. Force of the Center for Translational 
Medicine, which will allow us to evaluate 
the importance of CalDAG-GEFI in mouse 
models of myocardial infarction and 
ischemia-reperfusion injury in the heart. We 
are convinced that targeting CalDAG-GEFI 
could be a very powerful approach to interfere 
with these illnesses.” 
“Jefferson is an exciting place to be right 
now,” says Dr. Bergmeier, given its core 
group of people in the division who focus on 
platelet biology and platelet-driven diseases. 
“We also have a long tradition of caring for 
patients with bleeding and clotting disorders 
in our Hemophilia and Thrombosis Center. 
And the Center for Translational Medicine is 
one of the leading research institutions in the 
country with regard to understanding heart 
failure and heart disease. What we are starting 
to do now is to combine our forces.”  ■
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4The Department of Medicine benefits greatly 
from leaders who pair leading-edge research 
with clinical excellence. Joseph Cheung, MD, 
PhD, who joined Jefferson in October 2006 
as Chief of the Division of Nephrology and 
the Capizzi Professor of Medicine, embodies 
this dual commitment. In addition to his 
long list of responsibilities as Division Chief  
 — overseeing the finances of the division, 
expanding its activities, and recruiting new 
faculty  — Dr. Cheung also routinely sees 
patients and conducts an extensive program 
of NIH-funded cardiovascular research. 
In the two years under Dr. Cheung’s 
leadership, Nephrology has increased from 
five to ten faculty members, and he has 
expanded the division’s clinical activities 
as well as its profile. In addition to three-
month rotations on inpatient nephrology 
consultation, he works the same number 
From Patient Rounds to Mouse Cell Research:
Nephrology Chief Covers All the Angles
Nephrology
of nights and weekends as the other faculty 
members in the division.
Born and raised in Hong Kong, Dr. Cheung 
left to attend McGill in Montreal, where he 
obtained a BS with First Class Honors in 
Biophysics. He enrolled in the combined MD-
PhD program at Penn State where he obtained 
his PhD in Physiology, and completed his MD 
studies at Duke. It was as a first-year medical 
student at Penn State that Dr. Cheung met 
his wife, Barbara A. Miller, MD, now the 
Four Diamonds Professor of Pediatrics, Vice-
Chairman of Pediatric Research, and Chief of 
Pediatric Hematology/Oncology at Penn State. 
She is Principal Investigator on NIH-funded 
research on hematopoiesis.
Dr. Cheung’s training included a Medicine 
Residency at Duke and Nephrology Fellowship 
at Massachusetts General Hospital; he 
subsequently obtained faculty positions at 
Harvard and later Penn State, where he rose to   
Professor of Medicine (tenured) in 1991 and 
Chief of Nephrology in 1993. In 2000, to refo-
cus and retool his research skills, Dr. Cheung 
became Senior Scientist at the Weis Center for 
Research at Geisinger Medical Center. He was 
also named Director of Geisinger’s Pancreas 
Transplant Program in 2003.
Heart Cell Remodeling 
Dr. Cheung was elected in 1994 to the 
American Society for Clinical Investigation 
(ASCI), an honorific society that elects some 
60 members each year for their outstanding 
records of scholarly achievement in bio-
medical research. Throughout his career, Dr. 
Cheung has always focused on cardiovascular 
research. The first of his two major interests  — 
both of which are currently NIH funded 
 — explores heart cell remodeling after a heart 
attack and the mechanisms by which exercise 
training improves heart function in the wake 
of that event.
“We measure intracellular ions, ion currents, 
and the contraction of single heart cells,” 
explains Dr. Cheung. He works within 
Jefferson’s Center for Translational Medicine 
and surgically induces heart attacks in 
genetically engineered mice. “We actually 
have the mice running on a treadmill,” he 
explains, “in order to observe changes in the 
heart after heart attack, with and without 
exercise.” Apparently the mice take to the 
exercise regimen rather quickly and easily. 
“After three weeks, they can run quite fast,” 
says Dr. Cheung. “Within eight weeks, we 
start to see cellular changes.”
Sodium-Calcium Exchanger 
A second major interest is the regulation of 
cardiac sodium-calcium exchanger in the 
heart, which not only controls the force of 
the heartbeat but can generate irregular heart-
beats under pathological circumstances. “It 
is critical to understand this ion exchanger, 
especially when its function has been altered,” 
asserts Dr. Cheung.
Cardiac Cells in Mice 
His work in the Center for Translational 
Medicine involves isolating single cardiac 
cells and placing them in culture. “Mice offer 
unique advantages to the researcher because 
their genes are much easier to manipulate 
than those in larger animals,” Dr. Cheung 
explains. Yet mouse heart cells are very 
difficult to isolate and culture. “We put 
genetically altered heart cells in culture, and 
then use a virus to alter the expression of 
another gene of interest — at least in the 
short term.”
The work of Dr. Cheung’s lab is breaking 
ground in two areas. “Ours is the first lab to 
show that mouse heart cells retain normal 
contractility in culture for 48 hours,” he 
says, whereas previous research had shown 
contractility and other function for only 24 
hours. “Pictures taken at day two show the 
cells still maintain normal transverse-tubule 
architecture.” He adds, “We also are the first 
group to discover the first and only protein 
regulator (phospholemman) of sodium-
calcium exchanger in the heart.”
A minor interest of Dr. Cheung’s is 
erythropoietin, an agent that is widely used 
clinically to stimulate the growth of red 
blood cells in kidney failure patients and in 
patients receiving chemotherapy. “Our goal 
is to answer the question, ‘How does this 
work?’” he says. “More than 20 years ago, we 
were the first to report that erythropoietin 
increases intracellular calcium in red blood 
cell precursors.” Drs. Miller and Cheung 
have identified the erythropoietin-regulated 
calcium permeable ion channel, which belongs 
to the family of transient receptor potential 
(TRP) channels. “What is translational,” says 
Dr. Cheung, “is how erythropoietin promotes 
cell division and survival — and our goal 
is to understand the precise pathway so that 
better agents can be designed with fewer 
side effects.” ■
Joseph Cheung, MD, PhD, Chief of the Division of 
Nephrology, is expanding the division’s research and 
clinical activities.
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5Murray I. Blackman, Trustee of the Kahn 
Foundation, was kind enough to support 
Joseph Cheung, MD, PhD, in his work on 
chronic kidney diseases, and specifically, on 
ion transport in patients with high blood 
pressure (hypertension).
“High blood pressure is the most common 
cause of chronic kidney disease and kidney 
failure,” explains Dr. Cheung. “One-third of 
patients with kidney failure who are currently 
Gift Supports Research in High Blood 
Pressure and Kidney Disease
treated with dialysis have hypertension as the 
causative event.” Mr. Blackman’s generous gift 
supports his research in studying the mechanism 
of how a particular molecule is regulated. Dr. 
Cheung is hopeful that this research will provide 
a window through which to see the pathway 
of how hypertension causes kidney disease.
“One way to look at hypertension is to study 
smooth muscle cells,” says Dr. Cheung. 
“Alteration of ion homeostasis in vascular 
smooth muscle cells can cause stiffening of 
blood vessels and subsequent development 
of high blood pressure.” One of the ion 
transporters is sodium-calcium exchanger  — 
a target of Dr. Cheung’s research for several 
years, which has been intimately related to ion 
homeostasis in vascular smooth muscle.  ■
G i v i n g  t o  M e d i c i n e
Cath Lab Dedication
On May 14, 2008, Jefferson hosted the 
dedication of a newly renovated catheter-
ization laboratory (Cath Lab) with the 
corporate donor who funded the renovation 
with a $500,000 donation. The donor, N. J. Sky 
Cooper, is President/CEO of Charles Jacquin et 
Cie, Inc., America’s oldest producer of cordials, 
operating in Philadelphia since 1884. ■
(Left to right) Arthur Feldman, MD, PhD, Magee 
Professor and Chair of Medicine; Bernard L. Segal, 
MD, Director Emeritus, Division of Cardiology; N. J. 
Sky Cooper, President and CEO of Charles Jacquin et 
Cie, Inc.; Michael Savage, MD, Co-Director, Cardiac 
Catheterization Lab; and Tom Lewis, President and 
CEO of Thomas Jefferson University Hospital
As Clerkship Director and Assistant 
Residency Program Director for Internal 
Medicine, Gretchen Diemer, MD, has a 
direct impact on the career of every third-
year student in the Internal Medicine 
program at Jefferson  — which totals more 
than 250 people this year alone. 
After attending the University of Virginia 
Medical School and doing an internship 
and residency at Penn, Dr. Diemer came to 
Jefferson in 2004 and worked as a Hospitalist 
in Internal Medicine  — a hospital-based spe-
cialty that focuses on 
improving the quality 
of care for inpatients.
Dr. Diemer assumed her current role of 
Internal Medicine Clerkship Director in 2007, 
and finds her work in medical education 
to be a challenging and satisfying way to 
support the next generation of physicians. 
The Internal Medicine Clerkship program, 
which she oversees, takes place during the 
students’ third year.  This is a period of 
intense clinical experience, “when the students 
do what are essentially apprenticeships,” 
she says. “The idea is for each student to 
be exposed to a number of areas, to gain a 
strong understanding of internal medicine  
 — regardless of a particular specialty.”
The students rotate at Jefferson University 
Hospital for four of the 12 weeks of the 
clerkship, and for the other eight weeks rotate 
through one of seven other affiliated hospitals: 
Christiana Hospital in Delaware, York 
Hospital, Reading Hospital, UPMC Mercy 
in Pittsburgh, Methodist Hospital, Albert 
Einstein Medical Center, and the Wilmington 
Clerkship Director Gretchen Diemer: 
Shaping the Med Student Experience
VA Medical Center. Dr. Diemer helps the 
site directors to structure the program so that 
all students receive a consistent experience. 
“There’s a strong correlation between the 
quality of a student’s clerkship and the 
specialty that he or she ultimately chooses, so 
we take this part of the process very seriously.” 
She is also constantly seeking to recruit new 
sites to the clerkship program.
Dr. Diemer is also involved in curriculum 
development for the residency program and 
oversees evaluations that are written for 
every resident in the program. She spends 
time planning with medical students who are 
at the end of their third year, in terms of what 
electives to take. In addition, her position 
includes a fair amount of career advising. “I 
really enjoy my job,” Diemer says, “because 
Jefferson is a place that values education. It’s a 
pleasure to work at an institution that is com-
mitted to devoting resources to programs that it 
deems as so crucial to its mission.” ■
Gretchen Diemer, MD, 
directs the Internal 
Medicine Clerkship 
program, to enrich 
third-year students’ 
clinical experiences.
E d u c a t i o n
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6The Division of Rheumatology is growing 
and expanding under the leadership of its 
new Director, Oscar Irigoyen, MD. Named 
to the position in July 2008, Dr. Irigoyen had 
served as Acting Director since the spring of 
2007 and previously served as the Clinical 
Rheumatology Director.
Born and raised in Argentina, Dr. Irigoyen 
received a doctor of medicine degree 
from Buenos Aires University School of 
Medicine and completed a residency in 
Internal Medicine at the Medical Research 
Institute of Buenos Aires. He completed his 
fellowship in Rheumatology at the College of 
Physicians and Surgeons (P & S) of Columbia 
University in New York. He subsequently 
served as Assistant Professor at Columbia 
P & S Medicine and at the Albert Einstein 
College of Medicine. In 1987, he returned to 
Columbia University and rose to Associate 
Clinical Professor of Medicine, a position he 
held until coming to Jefferson in 2006.
Dr. Irigoyen explains that Jefferson is a major 
referral center for rheumatology in the tri-state
area. “Much of the emphasis in the division 
now is clinical – seeing patients and doing 
clinical research,” he says. The size of the divi-
sion is currently five faculty members, and Dr. 
Irigoyen seeks to recruit additional physicians 
in order to meet the increasing demand.
Disease-Specific Centers 
To ensure the best of care the Division of 
Rheumatology has continued to expand 
and create new disease-specific Centers 
of Excellence. “The patients who move in 
and out of Jefferson every day are actively 
involved in their own education about their 
health,” says Dr. Irigoyen, “and we are 
constantly striving to improve the programs 
and resources we make available to them.” 
In May 2008 two of Rheumatology’s centers 
were highlighted in Philadelphia magazine as 
Centers of Excellence: Jefferson Osteoporosis 
Center and the Lupus Center at Jefferson.
Although the Jefferson Osteoporosis Center 
is located in Bala-Cynwyd and the Lupus 
Center is located in Center City, consultation 
services for those conditions are provided at 
both locations.
The Arthritis Center treats patients 
with inflammatory disorders, including 
rheumatoid arthritis and psoriatic arthritis. 
These chronic conditions are characterized 
by inflammation of the lining of the joints (in 
rheumatoid arthritis) and inflammation of 
the skin and joints in psoriatic arthritis (also 
known as psoriasis when it affects only the 
skin). “In the past we could never get patients 
into complete remission; the treatment we 
had available would not completely prevent 
progressive damage to the joints,” he says. 
“With the advent of the new biologicals, 
now the majority of patients can go into 
remission within 4 to 8 weeks, depending on 
the medication.” Some of these new drugs are 
administered intravenously at the Division’s 
Infusion Centers at Bala-Cynwyd and Center 
City. The centers also treat conditions such as 
uveitis, an inflammation of the eye, as well as 
other dermatological conditions. Dr. Irigoyen 
explains that “new types of medications 
developed in just the past few years make a 
huge difference for patients.”
Research Studies 
The Osteoporosis, Arthritis, and Lupus 
Centers are currently participating in 
clinical research studies on the conditions 
of osteoporosis, rheumatoid arthritis, 
scleroderma, and lupus. Rheumatology also 
collaborates with other Jefferson departments 
and divisions on a number of projects. One 
of the collaborations is with Dr. Charlene 
Williams in the Center for Translational 
Medicine, to identify gene abnormalities in 
conditions classified as autoinflammatory 
or in conditions that cannot be classified. 
“Symptoms of these conditions range 
from recurrent fevers to rashes that have 
no apparent explanation,” Dr. Irigoyen 
says. “Our hope is to identify specific gene 
abnormalities, so that we can diagnose the 
disease more effectively, and understand the 
mechanisms of the disease, which can lead to 
a more rational treatment.”
Dr. Irigoyen emphasizes that this has been a 
time of growth for the division. The Infusion 
Centers have been expanded and renovated, 
and the planning process is underway for 
construction of a new clinical area at the 
Center City location on the 6th floor of 
Walnut Towers.
New Director Builds on 
Centers of Excellence
Oscar Irigoyen, MD, Director, Division of 
Rheumatology, plans to expand the division and 
improve disease-specific centers to meet increased 
patient demand.
“This is a time of movement forward and 
expansion, as we strive to make our clinical 
centers the best in Philadelphia as well as 
Pennsylvania,” Dr. Irigoyen says. ■
Rheumatology
Prestigious $11.6M Grant Supports Study 
of Heart Failure, continued from page 1
Dr. Koch’s group will focus on the role of 
the enzyme GRK5 in regulating gene tran-
scription and growth of heart cells, which 
can cause cardiac enlargement and heart 
failure. A group led by Arthur Feldman, 
MD, PhD, Magee Professor and Chair of the 
Department of Medicine, focuses on the role 
of signaling through the heart’s adenosine 
receptors. A third group is led by Thomas 
Force, MD, James C. Wilson Professor of 
Medicine and Clinical Director of the Center 
for Translational Medicine, and will continue 
studies of cancer drugs called tyrosine kinase 
inhibitors to understand how they affect heart 
cells including cardiac stem cells. ■
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7Jefferson University Physicians (JUP) 
participated in a pilot project from July 
through December 2007 called the Physician 
Quality Report Initiative (PQRI), sponsored 
by the Centers for Medicare and Medicaid 
Services (CMS). This quality initiative aims to 
measure and improve physicians’ performance 
in ambulatory care (outpatient) settings.
Many of the JUP practices agreed to participate, 
and although the project is ongoing, CMS 
has reported on the initial period. Assistant 
Director of Clinical Outcomes Research, 
Suzanne Adams, RN, MPH, supported PQRI 
for the Division of Cardiology and explains 
that the Division had both the highest level 
of participation and the best performance 
ratings of those Jefferson practices involved, 
including Family Medicine, Anesthesiology, 
Dermatology, and other medical and surgical 
sub-specialties. “We are proud to report that 
a total of 31 Jefferson Heart Institute (JHI) 
Preparing for the Future of Clinical Medicine: 
Pay-for-Performance Programs
Cardiology
physicians participated, and of those, 27 met 
the PQRI standard,” she says. Some of the 
cardiology quality indicators this project 
evaluates include evidence-based medication 
management and appropriate testing for 
common diagnoses such as myocardial 
infarction and heart failure.
PQRI is related to a new value-based purchasing 
initiative that CMS intends to implement, 
where the organization takes a closer look at 
the services for which reimbursements are 
requested. The quality performance measures 
address over 180 diagnoses.
The advantage to strong performance in this 
initiative is that it strengthens the position of 
Cardiology to become eligible for reimburse-
ment on Medicare billing, and also to measure 
and respond to quality indicators. However, 
there is also a prognostic side to the program. 
“When it’s time for cutbacks, as is inevitable 
in the current economic climate,” says Adams, 
“strong PQRI performance means that prac-
tices like ours will not be affected because we 
meet that quality standard. This translates into 
a standards-based clinical environment that 
will stave off reimbursement cuts.”
“This is an important model not just for 
Medicare, but for all private payors who are 
playing an increasingly significant role in 
medical care,” says Adams. Insurers such as 
Aetna and Independence Blue Cross are right 
behind CMS in terms of the same process of 
measuring and enhancing quality of care.
“We are pleased that the Jefferson Cardiology 
Group has worked together so effectively to 
achieve such strong performance  — from 
doctors and clinicians to billing and adminis-
tration staff,” Adams says. “At JHI we will 
continue with this ongoing initiative, always 
striving higher for optimal standards of care.” ■
Leon Peris Award
On June 11, Jefferson Medical College 
presented the 2008 Leon A. Peris Memorial 
Award to Alfred O. Moon, MD, a graduating 
internal medicine resident. The award is 
given to a graduating resident who exhibits 
excellence in the completion of medical 
records. Dr. Moon is pursuing an Allergy and 
Clinical Immunology Fellowship at Kaiser 
Permanente in Southern California.  ■
Awards and 
Honors
Paul Bray, MD, Thomas Drake Martinez 
Cardeza Professor of Medicine and Director 
of the Division of Hematology, has co-
authored a research study indicating that 
postmenopausal women can take a simple 
blood test to determine whether hormone 
therapies present an elevated risk of heart 
attack. The paper was published in the 
April 3, 2008, issue of the American Journal 
of Cardiology. The study was part of the 
Women’s Health Initiative sponsored by the 
National Heart, Lung, and Blood Institute of 
the National Institutes of Health (NIH).
Sharon Rubin, MD, Associate Professor of 
Cardiology, received a Humanitarian Award 
from Jefferson Medical College on Awards 
Day, May 29, 2008.
Paul Mather, MD, Professor and Director 
of the Advanced Heart Failure and Cardiac 
Transplant Center at the Jefferson Heart 
Center, has been chosen to serve as the 
program co-chair for the 2010 American 
College of Cardiology Annual Meeting.
Kathleen Squires, MD, Director of 
the Division of Infectious Diseases and 
Environmental Medicine, was appointed 
Chairperson of the NIH AIDS Clinical 
Studies and Epidemiology (ACE) Study 
Section. The term runs July 2008–June 2010.
Behzad Pavri, MD, Associate Professor 
of Cardiology, was invited to serve as the 
keynote speaker for the inauguration of the 
Therapy and Procedure Training Center in 
Chennai, India in July 2008. ■
F a c u l t y  N e w s
Right (left to right): 
Arthur Feldman, MD, 
PhD, Chair of Medicine; 
Dr. Moon; David Nash, 
MD, MBA, Founding 
Dean of the new 
School of Population 
Health; and Albert 
Worthington, Director 
of Health Information 
Management. 
7
et al.: Jefferson Translations, Vol. 4, No. 1, Winter 2009
Published by Jefferson Digital Commons, 2010
Translations
Department of Medicine
1025 Walnut Street, Suite 822
Philadelphia, PA 19107-5083
Non-Profit Org.
U.S. Postage
PAID
Bensalem, PA
Permit No. 182
Writer and editor: Alison Rooney   
Design: JeffGraphics
Photography: Jim Graham, Robert Neroni
©2009 Thomas Jefferson University
Translations is published several times a year 
by the Department of Medicine at Thomas 
Jefferson University (www.Jefferson.edu/medicine). 
For more information call 215-955-6946 or write to 
the address below.
The Department of Medicine 
encompasses 9 divisions and 6 centers: 
Cardiology
Howard H. Weitz, MD, Director 
 Center for Outcomes Research
Critical Care, Pulmonary, Allergic, 
and Immunologic Diseases
Gregory C. Kane, MD, Interim Director
Endocrinology, Diabetes, 
and Metabolic Diseases
Serge A. Jabbour, MD, Interim Director
Gastroenterology and Hepatology
Anthony J. DiMarino, MD, Director
Hematology
Paul F. Bray, MD, Director
 Hematology/Cardeza Foundation 
 for Hematologic Research 
Infectious Diseases and 
Environmental Medicine
Kathleen E. Squires, MD, Director
 Center for Biodefense
 Center for Human Virology
Internal Medicine
Barry S. Ziring, MD, Director
 Center for Vascular Diseases
Nephrology
Joseph Y. Cheung, MD, PhD, Director
 Center for Novel Therapies 
 in Kidney Disease
Rheumatology
Oscar Irigoyen, MD, Director
Center for Translational Medicine
Walter J. Koch, PhD, FAHA, Director,
Vice Chair for Research, and
W.W. Smith Professor of Medicine
The following faculty members have joined the 
Department of Medicine as of January 2009:
Cardiology
Deborah August, MD
Kimberly French, MD 
Gregory Marhefka, MD
Center for Translational Medicine
David M. Harris, PhD
Jifen Li, PhD
Gastroenterology
Bob Etemad, MD
Marianne Ritchie, MD
Welcome New Faculty
Hematology
Michael Holinstat, PhD
John Kark, MD
Internal Medicine 
William Chong, MD
Allison Johnson, MD
Joanna Kipnes, MD
Mary Kate McCullen, MD 
Rola Rimawi, MD
Justin Vadaparampil, MD
Jennifer Valentine, MD
JG
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Infectious Disease
Deena Athas, MD 
William Short, MD 
Nephrology
Stephanie DeLoach, MD
Dan Negoianu, MD
Pooja Singh, MD
Pulmonary/Critical Care/Sleep
Ritu G. Grewal, MD
Rheumatology
Michele Meltzer, MD
Faculty member David Axelrod, MD (far left), Residency Program Director 
Gregory Kane, MD (4th from right), and Department Chair Arthur Feldman, 
MD, PhD, congratulate students and physicians in training who won 
honors at the American  College of Cardiology poster competition (see 
background), including graduating JMC seniors (from left to right) Nisha 
Aggarwal, Katie Hawthorne, Erin Toto, and Mahdi Chowdhury as well as 
3rd-year medical resident Paul Sagar, MD (2nd from right) and cardiology 
fellow Siva Kumar, MD (3rd from left). Not pictured: David Whellan, MD, 
MHS, Director of Clinical Outcomes Research.
ACC Poster Competition Winners
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